Clifton Life Sciences

CLS is a life sciences company that has developed and is commercializing an innovative blood-based molecular signature platform. The molecular signature profile platform combines CLS’ proprietary genomic profiles with our advanced informatics and data management software. CLS offers this solution as an innovative, end-to-end service that can be outsourced and provide customers with data that is immediately ready to be used for diagnostic and therapeutic molecular biomarker based clinical management.

A unique mix of expertise in endocrine disease

Clifton Life Sciences provides a unique diagnostic mix of expertise in oncology, gastroenterology, bronchopulmonary, neuroendocrinology and biomathematics. It has a proven track record in the development of peripheral blood signatures for neuroendocrine and prostate cancers diagnosis and management. The company aim is to identify and develop peripheral blood markers that may serve as more accessible surrogates to detect other cancers including breast, colon, lung, ovarian, pancreas, melanoma and myeloma. Our goal is to develop in vitro diagnostics that are not only diagnostic but predictive of drug treatment efficacy and can evaluate response to therapy. Our blood PCR-based tests exhibit a >90% sensitivity and specificity.